Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Standard dosing is evidence-based, while microdosing, using lower-than-prescribed doses, has gained attention despite limited evidence, with potential benefits offset by concerns about reduced efficacy, safety risks, and lack of clinical validation
With all four core TRIUMPH trials now complete TRIUMPH-4 (December 2025, 28.7% weight loss), TRIUMPH-1 (May 2026, 28.3% in 2,339 patients), TRIUMPH-2 (July 2026, obesity + diabetes), and TRIUMPH-3 (July 2026, obesity + cardiovascular disease) plus TRANSCEND-T2D-1 (June 2026, the first diabetes-specific Phase 3 readout), this investigational medication now has the full data package Eli Lilly says it needs for regulatory submission
The trial-documented cadence is roughly every four weeks , and only if the current step is well tolerated
Timing does not eliminate side effects, but evening dosing isolates nausea and flushing to sleep hours when they are least disruptive
US$ 23.47
US$ 20.38
US$ 28.52
US$ 26.33
US$ 28.15
US$ 20.86
